Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation

Transplantation

Volumn 66, Issue 11, 1998, Pages 1460-1464

  Pascual, Manuel ^a   Saidman, Susan ^a   Tolkoff Rubin, Nina ^a   Williams, Winfred W ^a   Mauiyyedi, Shamila ^a   Duan, Ji Ming ^a   Farrell, Mary Lin ^a   Colvin, Robert B ^a   Cosimi, A Benedict ^a   Delmonico, Francis L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; STEROID; TACROLIMUS;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ANTIBODY FORMATION; BIOPSY; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PLASMA EXCHANGE; TACROLIMUS;

EID: 0032535230     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199812150-00008     Document Type: Article

References (27)

1. Jeannet M, Finn VW, Flax MH, Winn HJ, Russell PS. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970; 282: 111.
2. Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of anti-class I antibody response. I. Clinical and pathologic features of anti-class I mediated rejection. Transplantation 1990; 49: 85.
3. Halloran PF, Schlaut J, Solez, Srinivasa NS. The significance of anti-class I response: clinical and pathologic features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: 550.
4. Ahern AT, Artruc SB, Della Pelle P, et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocyte and endothelial reactive antibodies. Transplantation 1982; 33: 103.
5. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: 1464.
6. Colvin RB. The renal allograft biopsy. Kidney Int 1996; 50: 1069.
7. Trpkov K, Campbell P, Pazderka F, Cockfield S, Solez K, Halloran PF. Pathologic features of acute renal allograft rejection associated with donor-specific antibody: analysis using the Banff grading schema. Transplantation 1996; 61: 1586.
8. Lobo PI, Spencer CE, Stevenson WC, Pruett TL. Evidence demonstrating poor kidney graft survival when acute rejections are associated with IgG donor-specific lymphocytotoxin. Transplantation 1995; 59: 357.
9. Martin S, Dyer PA, Mallick NP, Gokal R, Harris R, Johnson RWG. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: 50.
10. Baldwin WM III, Sanfilippo F. Antibodies and graft rejection. Transplant Proc 1989; 21: 605.
11. Delmonico FL, Tolkoff-Rubin N, Auchincloss H Jr, et al. Management of the renal allograft recipient: immunosuppressive protocols for long-term success. Clin Transplant 1994; 8: 34.
12. Collins AB. Immunofluorescence. In: Colvin RB, Bhan AK, McCluskey RT, eds. Diagnostic immunopathology. New York: Raven Press 1995; 699.
13. Schneeberger EE, Collins AB, Latta H, McCluskey RT. Diminished glomerular accumulation of colloidal carbon in autologous immune complex nephritis. Lab Invest 1977; 37: 9.
14. Delmonico FL, Fuller A, Cosimi AB, et al. New approaches to donor crossmatching and successful transplantation of highly sensitized patients. Transplantation 1983; 36: 629.
15. Fitzpatrick D, Drew L, Saidman SL. A simple method for removal of OKT3 from patient sera [Abstract]. Hum Immunol 1996; 49 (suppl 1): 108.
16. Nickeleit V, Vamvakas EC, Pascual M, Poletti J, Colvin RB. The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 1998; 9: 1301.
17. Williams GM, Hume DM, Hudson RP Jr, Morris PJ, Kano K, Milgrom F. "Hyperacute" renal homograft rejection in man. N Engl J Med 1968; 279: 61.
18. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
19. Higgins RM, Bevan DJ, Carey BS, et al. Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348: 1208.
20. Madore F, Lazarus JM, Brady HR. Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 1996; 7: 367.
21. Colvin RB. The pathogenesis of vascular rejection. Transplant Proc 1991; 23: 2052.
22. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathological criteria for acute renal allograft rejection: reproducibility, sensitivity and clinical correlation. J Am Soc Nephrol 1997; 8: 1930.
23. Jordan ML, Naraghi R, Shapiro R, et al. Tacrolimus rescue therapy for renal allograft rejection: five year experience. Transplantation 1997; 63: 223.
24. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996; 61: 722.
25. Kimball JA, Pescovitz MD, Book BK, Norman DJ. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379.
26. Halloran PF. Immunosuppressive agents in clinical trials in transplantation. Am J Med Sci 1997; 313: 283.
27. Hammond EH, Yowell RL, Nunoda S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications. J Heart Transplant 1989; 8: 430.